echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical Research Articles > Mallinckrodt's terlipressin key phase 3 test CONFIRM reaches major and secondary endpoints

    Mallinckrodt's terlipressin key phase 3 test CONFIRM reaches major and secondary endpoints

    • Last Update: 2020-06-08
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    recently,(http:// of the http://company of Mallinckrodt Bio
    Medicine sinannounced that its terlipressin had reached the main and all secondary end points of the trial in the key phase 3trial(http:///confirm
    /i for the treatment of type 1 liver and kidney syndrome (HRS-1)Mallinckrodt is expected to submitnew drug(http://application (NDA) for triebalin early next yearAbout terlipressinterlipressin is a precursordrug(http:// of the precursor of vascular pressure pressure, mainly acting on the visceral circulatory arterial smooth muscle V1 receptor, selectively constricting visceral blood vessels, reducing blood flow and pressure in the venous veins   Terlipressin has the effect of improving kidney function and promoting the excretion of sodium in the urine in patients with ascites   Up to 300 patients participated in the /confirm
    /i trial, a multicenter trial in the United States and Canada designed to verify the effectiveness and safety of triepressurein treatment HRS-1 The selected patients included patients with cirrhosis and ascites with acute renal failure, who did not respond to diuretics or albumin   The trial reached the main endpoint of reversing HRS symptoms, including improving kidney function, avoiding dialysis, and improving short-term survival in patients
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.